title: Treatment of idiopathic membranous nephropathy.
abstract: Exciting progress recently has been made in our understanding of idiopathic membranous nephropathy, as well as treatment of this disease. Here, we review important advances regarding the pathogenesis of membranous nephropathy. We will also review the current approach to treatment and its limitations and will highlight new therapies that are currently being explored for this disease including Rituximab, mycophenolate mofetil, and adrenocorticotropic hormone, with an emphasis on results of the most recent clinical trials.
authors.affiliation: Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA. waldmanm@niddk.nih.gov
authors.forename: Meryl
authors.initials: M
authors.lastname: Waldman
authors.forename: Howard A
authors.initials: HA
authors.lastname: Austin
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000477:Alkylating Agents / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D002986:Clinical Trials as Topic; D015433:Glomerulonephritis, Membranous / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D054507:Receptors, Phospholipase A2 / Q000276:immunology; D000069283:Rituximab
chemical_list: D000477:Alkylating Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D054507:Receptors, Phospholipase A2; D000069283:Rituximab; D000324:Adrenocorticotropic Hormone; D009173:Mycophenolic Acid